<DOC>
	<DOCNO>NCT01316822</DOCNO>
	<brief_summary>This Phase 1 study patient advance cancer receive investigational study drug ARRY-382 . Patients receive increase dos study drug order achieve high dose study drug possible cause unacceptable side effect . Patients follow see side effect effectiveness study drug , , treat cancer . Approximately 50 patient US enrol study .</brief_summary>
	<brief_title>A Study ARRY-382 Patients With Selected Advanced Metastatic Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>Key A histologically cytologically confirm diagnosis advance metastatic solid cancer refractory standard treatment , standard therapy available patient refuse standard therapy . Measurable disease evaluable , nonmeasurable disease . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 . Hemoglobin ≥ 9.0 g/dL , ANC &gt; 1500/uL platelet count ≥ 100,000/uL . AST/serum glutamic oxaloacetic transaminase ( SGOT ) ALT/serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5 × upper limit normal ( ULN ) . Bilirubin ≤ ULN . Serum creatinine ≤ 1.5 × ULN . Potassium , magnesium calcium ( correct calcium serum albumin level abnormal ) within normal range . Additional criterion exist . Key 12lead ECG demonstrate mean QTcF &gt; 450 msec ( triplicate assessment ) Screening Visit history/evidence long QT syndrome . History acute coronary syndrome , include unstable angina , coronary angioplasty , stenting , within past 24 week . Use concomitant medication prolong QT/QTc interval , assess Investigator , within 14 day prior first dose study drug . Use concomitant medication strong CYP3A inhibitor inducer within 14 day prior first dose study drug . Class II , III IV heart failure define New York Heart Association ( NYHA ) functional classification system . Uncontrolled symptomatic brain metastasis ( patient brain metastasis steroid , steroid dose must stable least 30 day ) . Active refractory nausea vomiting , chronic gastrointestinal disease ( e.g. , inflammatory bowel disease ) significant bowel resection , judgment Investigator , would preclude adequate absorption ( previous Whipple procedure allow ) . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>CSF1R</keyword>
	<keyword>M-CSF</keyword>
	<keyword>CSF-1</keyword>
	<keyword>c-FMS</keyword>
	<keyword>Tumor-associated macrophage</keyword>
	<keyword>Macrophage-Colony Stimulating Factor-1</keyword>
	<keyword>Receptor tyrosine kinase inhibitor</keyword>
	<keyword>Tumor cell-induced osteolysis</keyword>
</DOC>